Genetic Alterations in Early-Stage Pulmonary Large Cell Neuroendocrine Carcinoma

Cancer

Volumn 100, Issue 6, 2004, Pages 1190-1198

  Hiroshima, Kenzo ^a   Iyoda, Akira ^a   Shibuya, Kiyoshi ^a   Haga, Yukiko ^a   Toyozaki, Tetsuya ^a   Iizasa, Toshihiko ^a   Nakayama, Toshinori ^a   Fujisawa, Takehiko ^a   Ohwada, Hidemi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Large cell neuroendocrine carcinoma; Loss of heterozygosity; Lung; Methylation; p16; p53; Retinoblastoma protein; Small cell carcinoma

Indexed keywords

PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ALLELIC EXCLUSION; ARTICLE; CANCER GRADING; CANCER SURGERY; CELL DIFFERENTIATION; CHROMOSOME 13Q; CHROMOSOME 5Q; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; FLUORESCENCE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC DISORDER; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG SMALL CELL CANCER; METHYLATION; NEUROENDOCRINE TUMOR; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SMALL CELL; DIAGNOSIS, DIFFERENTIAL; DNA METHYLATION; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1542374046     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20108     Document Type: Article

References (32)

1. World Health Organization. Histological typing of lung and pleural tumours, 3rd ed. Berlin: Spring-Verlag, 1999:7-12.
2. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer. 2001;91:1992-2000.
3. Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol. 1998;29:272-279.
4. Marchevsky AM, Gal AA, Shah S, Koss MN. Morphometry confirms the presence of considerable nuclear size overlap between "small cells" and "large cells" in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol. 2001; 116:466-472.
5. Virmani AK, Fong KM, Kodagoda D, et al. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer. 1998;21:308-319.
6. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res. 2000;60:4894-4906.
7. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996; 93:9821-9826.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
9. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820-823.
10. Hung J, Kishimoto Y, Sugio K, et al. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA. 1995;273:558-563.
11. Kishimoto Y, Sugio K, Hung JY, et al. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst. 1995;87:1224-1229.
12. Yoshino I, Fukuyama S, Kameyama T, et al. Detection of loss of heterozygosity by high-resolution fluorescent system in non-small cell lung cancer: association of loss of heterozygosity with smoking and tumor progression. Chest. 2003; 123:545-550.
13. Onuki N, Wistuba II, Travis WD, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer. 1999;85:600-607.
14. Ullmann R, Petzmann S, Sharma A, Cagle PT, Popper HH. Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung. Hum Pathol. 2001;32:1059-1063.
15. Gugger M, Burckhardt E, Kappeler A, Hirsiger H, Laissue JA, Mazzucchelli L. Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas. J Pathol. 2002;196:408-415.
16. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704-707.
17. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 1994;54:6078-6082.
18. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995;11:210-212.
19. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995;1:686-692.
20. Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E. Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene. 1998;16:497-504.
21. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene. 1994;9:3375-3378.
22. Shapiro GI, Edwards CD, Kobzik L, et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 1995;55:505-509.
23. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA. 1998;95:11891-11896.
24. Zochbauer-Muller S, Gazdar AF, Minna JD. Molecular pathogenesis of lung cancer. Annu Rev Physiol. 2002;64:681-708.
25. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther. 2001;1:61-67.
26. Iyoda A, Hiroshima K, Baba M, Saitoh Y, Ohwada H, Fujisawa T. Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors. Ann Thorac Surg. 2002;73:1049-1054.
27. Sozzi G, Sard L, De Gregorio L, et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res. 1997;57:2121-2123.
28. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res. 1999;59:3866-3869.
29. Herbst RA, Weiss J, Ehnis A, Cavenee WK, Arden KC. Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res. 1994;54:3111-3114.
30. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res. 1995;55:4800-4803.
31. Petersen S, Wolf G, Bockmuhl U, Gellert K, Dietel M, Petersen I. Allelic loss on chromosome 10q in human lung cancer: association with tumour progression and metastatic phenotype. Br J Cancer. 1998;77:270-276.
32. Gasparotto D, Vukosavljevic T, Piccinin S, et al. Loss of heterozygosity at 10q in tumors of the upper respiratory tract is associated with poor prognosis. Int J Cancer. 1999; 84:432-436.